OBJECTIVE: To investigate the weight-reducing effect of cimetidine in overweight patients with Type 2 diabetes. DESIGN: A 12-week clinical intervention study of 400 mg cimetidine prescribed three times daily in a randomised, double-blind, placebo-controlled design. SUBJECTS: Forty-three overweight patients with Type 2 diabetes (age 18 ± 65 y, body mass index (BMI) 27.2 ± 48.2 kgam 2 ). MEASUREMENTS: Body weight, BMI, body fat, waist and hip circumference, waistahip ratio, blood pressure, fasting blood glucose, HbA 1c , plasma concentrations of insulin, insulinaglucose ratio and lipids at the start and after 12 weeks, and daily recordings of appetite. RESULTS: Subjects given cimetidine (n 19) and placebo (n 24) lost 5.0 AE 2.2 kg (mean AE s.d.) and 1.3 AE 1.1 kg, respectively. Signi®cant reductions were observed in appetite, body fat (29.9 AE 6.6% to 25.3 AE 7.4%), waist circumference (111.5 AE 10.3 cm to 107.4 AE 10.6 cm), waistahip ratio (0.96 AE 0.08 to 0.94 AE 0.08), and systolic and diastolic blood pressure (reductions of 6.9 AE 11.4 mm Hg and 6.0 AE 6.6 mm Hg, respectively) in cimetidine group only. Signi®cant decreases in fasting concentrations of blood glucose, HbA 1c , plasma insulin, insulinaglucose ratio, plasma triglycerides and a signi®cant increase in plasma high-density lipoprotein cholesterol were observed in the cimetidine group only. CONCLUSIONS: Cimetidine reduces appetite and body weight, and improves metabolic control in overweight subjects with Type 2 diabetes.
Introduction
According to previous reports, there is a high prevalence of Type 2 diabetes among obese subjects. 1, 2 Hyperinsulinism and insulin resistance are characteristic features of both Type 2 diabetes and obesity (for review, see Ref. 3) . In obese subjects the insulin resistance is highly correlated to the mass of visceral fat. 4, 5 However, it remains controversial whether obesity is the major andaor an independent contributor to the insulin resistance in Type 2 diabetes. 6, 7 It is well recognized that weight reduction is associated with bene®cial effects on metabolic control. 8 A modest weight reduction may strongly improve the metabolic pro®le. 9 Weight reduction induces improved glycemic control, reduced hepatic glucose output, increased insulin action in the liver and the peripheral tissue, and improved insulin secretion. 10 However, a weight reduction to normalcy elicits a complete normalization of the peripheral insulin action in only few patients. 10 This implies a heterogeneous pathogenesis, with interactions at least between visceral obesity and genetic factors. 11 We have previously reported that the H 2 -receptor antagonist, cimetidine, reduces weight in healthy overweight subjects. 12 The mechanism of this effect is unknown. In rats, H 2 -receptor antagonists reduce appetite and weight gain by a non-gastric acid related mechanism. 13 We have shown that cholecystokinin (CCK) is a candidate mediator of this effect on satiety. 14 The objective of this study was to investigate the effect of cimetidine on body weight and metabolic pro®le in overweight patients with Type 2 diabetes in a randomized, double blind, placebo-controlled study.
Materials and methods

Subjects
Sixty-two patients with Type 2 diabetes were recruited from the outpatient ®les of two Norwegian hospitals. The inclusion criteria were age 18±65 y and body mass index (BMI) b 25 kgam 2 . Patients with serious cardial, renal or hepatic diseases were excluded. Patients treated with antacids, gastric acid antisecretory agents, insulin or corticosteroids were also excluded.
Study design
The patients were randomized into two groups according to BMI: the ®rst group, cimetidine (400 mg): (Nycomed, Oslo, Norway) and the second group placebo (identical in taste and appearance as cimetidine) (Pharmaceutical Department, University Hospital of Tromsù, Tromsù, Norway), prescribed three times daily, 30 min before meals. Patients were told to follow their own diet or eat less if not hungry, to perform their regular exercise program and not change their smoking habits during the study. The cimetidine dose was twice as high as that used in the former study 12 as it seemed to induce a stronger feeling of satiety (unpublished observation). This dose also increases the postprandial CCK response. 14 At the start, a physical examination was performed, including sitting blood pressure, height, weight, abdominal circumference (umbilical level), and hip circumference (tuberculum majus). BMI was calculated as kgam 2 . Body fat % was measured with near infrared technique (Futrex 5000: Futrex Corp., Gaithersburg, MA) as previously described. 15 These procedures were repeated at the end of the study.
Duration of the study was 12 weeks, with clinic visits scheduled at the same time each week. Subjects were weighed each week, side effects were recorded and the average degree of hunger before breakfast, lunch and supper during the previous week was recorded on a 10 cm visual analogue scale. Compliance with the drug treatment was checked by the returned dose packets; 80% compliance was considered acceptable.
Laboratory tests
Blood samples were drawn after an overnight fast at the start and after 12 weeks. The blood samples were withdrawn into vacutainer tubes containing EDTA (1 mgaml, ®nal concentration), and centrifuged at 1000 g for 10 min at 4 C. Blood glucose was measured by a glucose analyzer (Model 2300 STAT, Yellow Springs Instrument Co., Inc., Yellow Springs, OH). The rest of the plasma was immediately frozen (727 C) and stored for later measurements. HbA 1c was measured by the Diamat TM system from Bio-Rad Laboratories GmbH (Munich, Germany). Insulin was measured by a radioimmunoassay (RIA) method. 16 Plasma concentrations of cholesterol and triglycerides were measured using Hitachi 917 Automatic Analyzer from Boehringer Mannheim (Mannheim, Germany). Reagents, calibrators and controls were purchased from the manufacturer. High-density lipoprotein (HDL) cholesterol concentrations in plasma were measured after preparation of HDL according to the method described by Burstein et al.
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Ethics
The study was conducted according to the Helsinki declarations and with the approval of the Ethical Committee of The Health Region V, Norway.
Statistical analysis
Statistical analysis was performed in those patients who ful®lled the study according to the protocol. Differences in consecutive weight changes between the cimetidine and placebo group were evaluated using repeated measures multivariate analysis of variance (RM MANOVA). Loss in appetite was de®ned as a decrease of b 10% in the mean visual analogue scale (VAS) during treatment of an individual patient. Signi®cance between the treatment groups was tested by comparing the fraction of patients with loss in appetite in each group by using Fisher-Irwin exact test. In the remaining parameters, the signi®cance was tested for within-group comparison by paired Student's t test, and for between-group comparison by unpaired t tests. The signi®cance level was set at P`0.05.
Results
Subjects
Of the 62 subjects (31 in each group) randomized to active and placebo treatment, 60 subjects (31a29, in the cimetidine and placebo group, respectively) entered the study, that is, two patients were lost at inclusion due to reasons unknown ( Table 1) . Five of the patients were not included due to sudden events between the randomization and the start. Twelve subjects were excluded, four subjects due to side effects (one placebo subject with diarrhoea and three cimetidine subjects, one each with arthralgia, abdominal pain and vomiting). After termination of the treatment all subjects recovered completely. In the remaining patients the medication was well tolerated. The remaining 43 subjects (19a24), 14 women and 29 men, completed the study according to the protocol. Cimetidine reduces weight G Stùa-Birketvedt et al
Characteristics of patients
Characteristics of the patients are shown in Table 2 .
At the start of the study there were no signi®cant differences between age, gender, duration of Type 2 diabetes, patients on peroral antidiabetic medication, body weight, BMI, fat %, waist and hip circumferences or waistahip ratio (WHR). During the ®rst week of treatment, appetite measured by VAS was signi®cantly reduced in the cimetidine group and remained so throughout the study. No changes in appetite were observed in the placebo group (Figure 1 ).
There was a signi®cant weight loss in the cimetidine group (5.0 AE 2.1 kg (meanAE s.d.)) and in the placebo group (1.3AE 1.1 kg) ( Table 3 ). The weight loss was signi®cantly greater in the cimetidine group than in the placebo group (Figure 2) . BMI, fat %, waist circumference and WHR were reduced in the cimetidine group. In the placebo group, these variables were only signi®cantly changed for BMI ( Table  3 ). The weight loss consisted of 89% fat in the cimetidine group and 85% fat in the placebo group. There was a signi®cant reduction in the systolic (6.9AE 11.4 mm Hg) and diastolic (6.0AE 6.6 mm Hg) blood pressure in the cimetidine group only (Table 3) .
Biochemical parameters
There were no signi®cant differences between groups in baseline values of fasting blood glucose and HbA 1c , plasma concentrations of insulin and insulinaglucose ratio (Table 4 ). In the cimetidine group there were signi®cant reductions in the levels of HbA 1c , insulin and insulinaglucose ratio, but no signi®cant changes in the placebo group were observed.
There were no signi®cant differences in baseline plasma levels of cholesterol, triglycerides and HDL cholesterol between the two groups (Table 4) . During treatment there were signi®cant reductions in the plasma levels of triglycerides and signi®cant increases in the plasma levels of HDL cholesterol in the cimetidine group, but no signi®cant changes in these variables in the placebo group were observed. Signi®cant changes in the plasma concentrations of cholesterol were not seen in any group. Cimetidine reduces weight G Stùa-Birketvedt et al
Discussion
This study shows that cimetidine reduces body weight and appetite in overweight patients with Type 2 diabetes. This agrees with previous reports in healthy overweight subjects 12 and in rats. 13 The mechanism of this effect of the H 2 -receptor antagonist is not known, although we have previously reported that cimetidine increases the basal and postprandial plasma level of CCK, 14 and CCK may mediate satiety signals from the gut to the brain. 18 The cimetidine-induced weight reduction during the 12 week period was 5.1 kg, which represents a 5% reduction in body weight. In the previous study of healthy overweight subjects, 12 the weight reduction was 9.5 kg, which represents a 12% weight reduction during an eight week combined treatment of cimetidine and diet. Patients in the present study were already restricted to a diabetic diet, which may explain their smaller weight loss. In this study, the weight reduction was 0.4 kgaweek and consisted of 89% body fat, a rate considered optimal in preserving the lean body mass 19 and to prevent an undesirable weight cycling. 20 Finally, in this and in the previously reported study, 12 the reduction of appetite and weight was not attenuated during the observation period. Therefore, cimetidine appears to be a promising supplement to diet and exercise, in the long term treatment of obesity.
The cimetidine-induced weight reduction was associated with improved glycemic control, that is, reduction of fasting concentrations of blood glucose and HbA 1c , plasma insulin and the insulinaglucose ratio. This improvement was obtained with only a 5% reduction in body weight and without achieving the ideal body weight. This is in agreement with other studies where only a modest weight reduction improved glycemic control and insulin sensitivity. 8, 21 Moreover, the plasma concentrations of triglycerides and HDL cholesterol were both elevated (out of the normal range) at the start of the study. Obesity and Type 2 diabetes are both part of the metabolic syndrome where hypertriglyceridemia, low HDL cholesterol and increased free fatty acids are the characteristic metabolic pro®le. 3 In this study, the plasma concentrations of triglyceride and HDL cholesterol changed towards normalcy. This agrees with other reports where a modest weight reduction also improved the blood lipid pro®le. 8 The plasma concentration of cholesterol, however, was in the normal range at the start of the study and no signi®cant change in this variable was observed during the weight reduction.
Conclusion
During the study, there were reductions in the waist circumference and the WHR suggesting a reduction in visceral fat 22 and in blood pressure. Altogether, our study shows that cimetidine reduces appetite and body weight, and improves metabolic control in overweight patients with Type 2 diabetes. This should indeed reduce the risk of cardiovascular disease and contri- Cimetidine reduces weight G Stùa-Birketvedt et al bute to positive health bene®ts. However, it remains to be proved that the H 2 -receptor antagonist has long term effects beyond three months. As reported by others, 8 modest weight reduction caused substantial improvements in diabetic control, in spite of the fact that most of the patients remained obese. Fasting plasma concentrations of insulin and plasma insulinablood glucose ratio were normalized in almost all the patients in the cimetidine group. The insulin resistance appears at a BMI b 32 kgam 2 . 23 In the cimetidine group, the improvement in the insulin sensitivity, measured indirectly as the plasma insulina blood glucose ratio, is probably at least partly due to weight reduction.
In conclusion, cimetidine induces reductions in appetite and body weight and improves diabetic control, insulin sensitivity and blood lipids in overweight subjects with Type 2 diabetes. These effects are probably a result of weight reduction.
